search
Back to results

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

Primary Purpose

Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma; With Hepatocellular Carcinoma

Status
Recruiting
Phase
Phase 2
Locations
Taiwan
Study Type
Interventional
Intervention
Colchicine Tablets
Sponsored by
Kaohsiung Medical University Chung-Ho Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma Stage IIIB focused on measuring hepatocellular carcinoma, Cholangiocarcinoma, primary hepatic malignancy, palliative treatment, colchicine

Eligibility Criteria

20 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

(A). Primary hepatic malignancy including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, hepatocellular-cholangiocarcinoma, poorly differentiated or undifferentiated primary hepatic malignancy.

  1. Diagnosis of hepatocellular carcinoma: Patient has at least one of the following criteria: (1) positive for hepatocellular carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level > 400 ng/mL and has evidence of hepatocellular carcinoma on contrast-enhanced computed tomography or magnetic resonance imaging.
  2. Diagnosis of intrahepatic cholangiocarcinoma: Patient has at least one of the following criteria: (1) evidenced by cytology or pathology, (2) serum CA19-9 level > 10 times of normal upper limit and has evidence on contrast-enhanced computed tomography or magnetic resonance imaging, and no evidence of extrahepatic original malignancy.
  3. Diagnosis of hepatocellular-cholangiocarcinoma: concomitantly fit at least one of the items described in (a) and (b)
  4. Diagnosis of poorly differentiated or undifferentiated primary hepatic malignancy: Patient fits all of the following criteria: (1) evidenced of malignancy other than hepatocellular carcinoma, intrahepatic cholangiocarcinoma or hepatocellular-cholangiocarcinoma by cytology or pathology, (2) no evidence of extrahepatic original malignancy

(B). Primary hepatic malignant tumors unable to receive curative treatment indicate that the malignancy can not be completely eliminated by operative resection, liver transplantation or local abrasion therapy. Patient also needs to fit at least one of the following criteria: (1) evidence of distant metastasis or large vessels (intrahepatic first branch portal vein, portal main trunk, major hepatic vein or inferior vena cava) invasion, (2) unable to be controlled by transcatheter arterial chemoembolization including appearance of new rather than incompletely treated nodules within 3 months of chemoembolization, or chemoembolization fails

(C). The performance status of the patient based on the Eastern Cooperative Oncology Group (ECOG) belongs to 0 or 1 and the calculated Child score is below 8 points.

Exclusion Criteria:

  1. . life-threatening hemorrhage at the present time
  2. . life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus) at the present time
  3. . extrahepatic original malignancy unable to be controlled
  4. . serum creatinine level > 1.5 mg/dL.
  5. . Patient must receive long-term statin or fibrates drugs. The doses of these medications can not be altered.
  6. . Patient has white blood cell count < 1500/µL, platelet count < 30000/µL or hemoglobin < 9.0 gm/dL after medication.
  7. . Pregnant woman or plan to be a pregnant woman
  8. . allergy to colchicine or has history of severe side effects caused by colchicine
  9. . Patient has received systemic chemotherapy within 2 months before enrollment or plans to receive systemic chemotherapy in the future.
  10. . Patient is under or plans to receive other clinical trial testing drug.
  11. . Patient has severe malfunction of vital organs and can not participate in this study justified by the member of the research team.
  12. . Patient is under or plans to receive Chinese traditional medicine or herb drugs.
  13. . Patient is under or plans to receive hospice care.
  14. . Patient took other clinical trial testing drug within 3 months before enrollment.
  15. . Patient can not quit drug abuse or heavy alcohol drinking.

Sites / Locations

  • Kaohsiung Medical University HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

colchicine group

Arm Description

The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.

Outcomes

Primary Outcome Measures

survival
The overall survival of the participants

Secondary Outcome Measures

serious adverse effect
The events of serious adverse effect occurred during the study

Full Information

First Posted
February 2, 2020
Last Updated
October 4, 2023
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Collaborators
Kaohsiung Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04264260
Brief Title
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
Official Title
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 24, 2019 (Actual)
Primary Completion Date
July 31, 2025 (Anticipated)
Study Completion Date
July 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Collaborators
Kaohsiung Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration. Colchicine will be started from 2 tablets after meal twice per day (total 2 mg), adjust the dose ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated treatment cycles till the participants quit the trial. The control group will be originated from review of (1) patients treated by members of this research team with the same condition as the trial selected participants but not included in the trial, (2) patients with same condition as the trial selected participants reported in the literatures. The primary objective is to evaluate the palliative effects of colchicine on primary hepatic malignancy unable to receive curative treatment. The primary end point is survival of the participant. The Secondary objective is to evaluate the safety of patients treated by colchicine and the secondary end point is the side effects of colchicine.
Detailed Description
Study procedures Written informed consent before study specific procedures are undertaken. The investigators will explain the contents of the trial especially the information about the possible side effects, other alternative treatment and the right to withdraw based on the participant own willing to the candidates. Patient can choose to sign or not to sign the inform consent based on his/her own decision after completely understanding the investigators explanation. The process of the experiment Start to receive colchicine: Participant will start to receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). Adjustment the dosage of colchicine during study: based on the following steps: 2 tablets-2 tablets-2 tablets (three times per day, after meal, total 3 mg, maximum dose)<-> 2 tablets -1 tablet -2 tablets (three times per day, after meal, total 2.5 mg)<->2 tablets -2 tablets (twice per day, after meal, 2 mg, starting dose)<->1 tablet -1 tablet -1 tablet (three times per day, after meal, 1.5 mg, minimum dose) The colchicine dosage will be changed when the hepatic reserved function of the participant changes to Child score 8-9 points according to the following rules. 1 tablet after meal three times per day with total dose of 1.5 mg; continue 4 days and stop for 3 days (1 cycle) If the hepatic reserved function of the participant returns to Child score < 8 points, the dosage changes to starting dose. If the hepatic reserved function of the participant changes to Child score > 9 points, colchicine will be stopped and participant receives regular follow-up only. If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again according to the above steps of dose adjustment. If the participant has one of the following conditions, colchicine will be temporarily stopped. When the condition of the participant improves, colchicine will be given again after the judgment from the doctor of the research team. For participants unable to receive colchicine again, they will receive regular follow-up only. . There are life-threatening hemorrhage including gastrointestinal hemorrhage and hemorrhage from other vital organs such as lungs or brain. . There are life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus). . Patient has serum creatinine level > 1.5 mg/dL. . Patient has white blood cell count < 1500/µL, platelet count < 30000/µL or hemoglobin < 9.0 gm/dL after medication. . The research team decides that the participant is not suitable to continue the study caused by abnormality of any vital organ or severe side effects caused by the study. Colchicine will be temporarily stopped before non-curative operative resection of tumor or transcatheter arterial chemoembolization until participant has body temperature < 38 ℃, same hepatic reserved function as before, and serum creatinine level < 1.5 mg/dL. no need to stop colchicine during irradiation therapy, pure ethanol injection or local radiofrequency abrasion Colchicine needs to be temporarily reduced to half of the original dose when the participant will temporarily take P-Glycoprotein inhibitor or strong Cytochrome P450 3A4 inhibitor. The conditions for the participant to withdraw or terminate the trial: Participant suffers from systemic itching, nausea, vomiting, abdominal pain, fever, or skin rash after colchicine administration. Participant is unable to tolerate 1.5 mg total daily dose of colchicine for at least 4 cycles. This does not include temporarily reduce dose to total 1 mg during temporarily application of P-Glycoprotein inhibitor or strong Cytochrome P450 3A4 inhibitor. Follow-up procedures and items for the participants to co-operate: All participants will be followed according to the guide line of the National Health Council and the clinical practice in the treatment of hepatic malignancy. Ultrasonography, contrasted-enhanced computed tomography or magnetic resonance imaging will be performed within every 3 to 4 months. Chest x-ray and whole body bone scan will be followed based on the condition of the participants. Serum alpha-fetoprotein or CA19-9 will be determined within 3 months in participants with abnormal original levels. The complete blood count, hepatic and renal function will be determined at least one session every month. The participants are asked to visit investigators' outpatient clinic at least one session every month. Concomitant treatment: Permitted: non-curative operative resection of the tumor, local abrasion therapy, local irradiation therapy, transcatheter arterial chemoembolization, target therapy, immunotherapy Prohibited: systemic chemotherapy, other clinical trial testing drugs, Chinese traditional medicine, herb drugs Statistical analysis 1.Statistical Method for Efficacy / Safety measurements: (A) Survival analysis for efficacy: (log-rank test and median survival) colchicine combined with other therapy is better than other therapy without target drug or immunotherapy colchicine combined with other therapy is not inferior than target drug or immunotherapy combined with other therapy (B) Safety measurements The safety assessment is presented in a narrative statistical manner for the collection of participants' severe adverse events and adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma; With Hepatocellular Carcinoma, Hepatocellular Carcinoma Stage IV
Keywords
hepatocellular carcinoma, Cholangiocarcinoma, primary hepatic malignancy, palliative treatment, colchicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
open labeled
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
colchicine group
Arm Type
Experimental
Arm Description
The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.
Intervention Type
Drug
Intervention Name(s)
Colchicine Tablets
Intervention Description
three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
Primary Outcome Measure Information:
Title
survival
Description
The overall survival of the participants
Time Frame
through study completion, an average of 31 months
Secondary Outcome Measure Information:
Title
serious adverse effect
Description
The events of serious adverse effect occurred during the study
Time Frame
through study completion, an average of 31 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (A). Primary hepatic malignancy including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, hepatocellular-cholangiocarcinoma, poorly differentiated or undifferentiated primary hepatic malignancy. Diagnosis of hepatocellular carcinoma: Patient has at least one of the following criteria: (1) positive for hepatocellular carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level > 400 ng/mL and has evidence of hepatocellular carcinoma on contrast-enhanced computed tomography or magnetic resonance imaging. Diagnosis of intrahepatic cholangiocarcinoma: Patient has at least one of the following criteria: (1) evidenced by cytology or pathology, (2) serum CA19-9 level > 10 times of normal upper limit and has evidence on contrast-enhanced computed tomography or magnetic resonance imaging, and no evidence of extrahepatic original malignancy. Diagnosis of hepatocellular-cholangiocarcinoma: concomitantly fit at least one of the items described in (a) and (b) Diagnosis of poorly differentiated or undifferentiated primary hepatic malignancy: Patient fits all of the following criteria: (1) evidenced of malignancy other than hepatocellular carcinoma, intrahepatic cholangiocarcinoma or hepatocellular-cholangiocarcinoma by cytology or pathology, (2) no evidence of extrahepatic original malignancy (B). Primary hepatic malignant tumors unable to receive curative treatment indicate that the malignancy can not be completely eliminated by operative resection, liver transplantation or local abrasion therapy. Patient also needs to fit at least one of the following criteria: (1) evidence of distant metastasis or large vessels (intrahepatic first branch portal vein, portal main trunk, major hepatic vein or inferior vena cava) invasion, (2) unable to be controlled by transcatheter arterial chemoembolization including appearance of new rather than incompletely treated nodules within 3 months of chemoembolization, or chemoembolization fails (C). The performance status of the patient based on the Eastern Cooperative Oncology Group (ECOG) belongs to 0 or 1 and the calculated Child score is below 8 points. Exclusion Criteria: . life-threatening hemorrhage at the present time . life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus) at the present time . extrahepatic original malignancy unable to be controlled . serum creatinine level > 1.5 mg/dL. . Patient must receive long-term statin or fibrates drugs. The doses of these medications can not be altered. . Patient has white blood cell count < 1500/µL, platelet count < 30000/µL or hemoglobin < 9.0 gm/dL after medication. . Pregnant woman or plan to be a pregnant woman . allergy to colchicine or has history of severe side effects caused by colchicine . Patient has received systemic chemotherapy within 2 months before enrollment or plans to receive systemic chemotherapy in the future. . Patient is under or plans to receive other clinical trial testing drug. . Patient has severe malfunction of vital organs and can not participate in this study justified by the member of the research team. . Patient is under or plans to receive Chinese traditional medicine or herb drugs. . Patient is under or plans to receive hospice care. . Patient took other clinical trial testing drug within 3 months before enrollment. . Patient can not quit drug abuse or heavy alcohol drinking.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zu Y Lin, MD
Phone
88673121101
Ext
7475
Email
linzuyau@yahoo.com.tw
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zu Y Lin, MD
Organizational Affiliation
Kaohsiung Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaohsiung Medical University Hospital
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zu Y Lin, MD
Phone
88673121101
Ext
7475
Email
linzuyau@yahoo.com.tw
First Name & Middle Initial & Last Name & Degree
Zu Y Lin, MD
First Name & Middle Initial & Last Name & Degree
Wan L Chuang, PhD
First Name & Middle Initial & Last Name & Degree
Ming L Yu, PhD
First Name & Middle Initial & Last Name & Degree
Chia Y Dai, PhD
First Name & Middle Initial & Last Name & Degree
Shinn C Chen, PhD
First Name & Middle Initial & Last Name & Degree
Jee F Huang, PhD
First Name & Middle Initial & Last Name & Degree
Chung F Huang, PhD
First Name & Middle Initial & Last Name & Degree
Ching I Huang, MD
First Name & Middle Initial & Last Name & Degree
Po C Liang, MD
First Name & Middle Initial & Last Name & Degree
Cheng T Hsu, MD
First Name & Middle Initial & Last Name & Degree
Po Y Hsu, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
16967451
Citation
Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce de Leon S, Kershenobich D, Leon-Rodriguez E. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer. 2006 Oct 15;107(8):1852-8. doi: 10.1002/cncr.22198.
Results Reference
background
PubMed Identifier
20586571
Citation
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348.
Results Reference
background
PubMed Identifier
16186437
Citation
Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005 Sep 27;112(13):2012-6. doi: 10.1161/CIRCULATIONAHA.105.542738.
Results Reference
background
PubMed Identifier
17242135
Citation
Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, Schaefer C, Stojanov S, Timmann C, Keitzer R, Ozdogan H, Ozen S. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83. doi: 10.1542/peds.2006-1434. Epub 2007 Jan 22.
Results Reference
background
PubMed Identifier
1959847
Citation
Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology. 1991 Dec;14(6):1013-5.
Results Reference
background
PubMed Identifier
7957521
Citation
Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol. 1994;46(4):351-4. doi: 10.1007/BF00194404.
Results Reference
background
PubMed Identifier
8930773
Citation
Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol. 1996 Oct;36(10):874-83. doi: 10.1002/j.1552-4604.1996.tb04753.x.
Results Reference
background
PubMed Identifier
20131255
Citation
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr;62(4):1060-8. doi: 10.1002/art.27327.
Results Reference
background
PubMed Identifier
23871804
Citation
Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013 Sep 3;93(8):323-8. doi: 10.1016/j.lfs.2013.07.002. Epub 2013 Jul 16.
Results Reference
background
PubMed Identifier
25910557
Citation
Wu CC, Lin ZY, Kuoc CH, Chuang WL. Clinically acceptable colchicine concentrations have potential for the palliative treatment of human cholangiocarcinoma. Kaohsiung J Med Sci. 2015 May;31(5):229-34. doi: 10.1016/j.kjms.2015.01.008. Epub 2015 Mar 10.
Results Reference
background
PubMed Identifier
26944324
Citation
Lin ZY, Kuo CH, Wu DC, Chuang WL. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci. 2016 Feb;32(2):68-73. doi: 10.1016/j.kjms.2015.12.006. Epub 2016 Feb 2.
Results Reference
background

Learn more about this trial

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

We'll reach out to this number within 24 hrs